Search

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

114.31 4.2

Resumen

Variación precio

24h

Actual

Mínimo

107.52

Máximo

116.99

Métricas clave

By Trading Economics

Ingresos

64M

-41M

Ventas

21M

92M

BPA

-0.61

Margen de beneficios

-44.904

Empleados

414

EBITDA

7.8M

-36M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+36.21% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.5B

7.9B

Apertura anterior

110.11

Cierre anterior

114.31

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 nov 2026, 21:01 UTC

Rhythm Pharmaceuticals, Inc. is trading significantly higher today, with unusually high market volume and currently positioned near the upper end of its one-month range.

12 nov 2026, 21:13 UTC

Rhythm Pharmaceuticals, Inc. is trading modestly higher in after-market hours, reflecting a cumulative return of nearly 1% following Thursday's close.

11 nov 2026, 22:01 UTC

Rhythm Pharmaceuticals, Inc. is trading lower in after-market hours, having declined below Wednesday's close before recovering slightly from an initial low.

10 nov 2026, 20:46 UTC

News

Rhythm Pharmaceuticals shares are higher as the company reports a significant rise in IMCIVREE sales and speculation of a $124 takeover bid from AstraZeneca.

9 nov 2026, 21:07 UTC

Rhythm Pharmaceuticals, Inc. shares advanced, maintaining a higher trajectory since Friday's close, with overall performance robust and trading above its 20-day moving average.

6 nov 2026, 23:46 UTC

Rhythm Pharmaceuticals, Inc. is experiencing a slight decline in after-market trading, moving lower from a peak shortly after the market closed.

5 nov 2026, 23:31 UTC

Rhythm Pharmaceuticals, Inc. shares are moving lower in after-market trading, reflecting a decline since Thursday's close amid broader market downturns.

4 nov 2026, 23:02 UTC

Social Media
Event
News

AstraZeneca made a non-binding offer of about $10 billion to acquire Rhythm Pharmaceuticals, proposing $124 per share, according to The Wall Street Journal.

3 nov 2026, 21:02 UTC

News

Rhythm Pharmaceuticals reports a Q3 net loss of $42.4 million, or $0.61 per share, exceeding revenue estimates but falling short of analyst expectations.

2 nov 2026, 21:04 UTC

Rhythm Pharmaceuticals, Inc. shares are trading higher today, with notable volume and positioning above their 20-day moving average, despite an earlier pullback.

30 oct 2026, 20:08 UTC

Correlated Moves

Rhythm Pharmaceuticals shares are declining amid a broader downturn in the biotechnology sector, influenced by significant drops in the SPDR S&P Biotech ETF (XBI).

28 oct 2026, 20:07 UTC

Macro Event

Rhythm Pharmaceuticals shares are declining amid broader market volatility following the Federal Reserve's decision to maintain interest rates steady.

27 oct 2026, 20:07 UTC

Correlated Moves

Rhythm Pharmaceuticals, Inc. shares are advancing, supported by a broader rally in the biotechnology sector and gains in the SPDR S&P Biotech ETF (XBI).

22 oct 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares are advancing amid a significant upward movement in the Biotechnology sub-sector, gaining ground since Wednesday's close.

21 oct 2026, 19:46 UTC

News

Shares of Rhythm Pharmaceuticals Inc fell sharply, trading significantly below its 20-day moving average ahead of its Q3 2026 financial results announcement on November 3, 2026.

20 oct 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is trading higher in after-market hours, continuing a trend of three consecutive sessions that have also closed higher.

19 oct 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading on Monday.

15 oct 2026, 20:07 UTC

News

Rhythm Pharmaceuticals receives an Overweight rating from JPMorgan, with the price target adjusted to $145.00, reflecting a continued positive outlook.

14 oct 2026, 19:56 UTC

News
Event

Rhythm Pharmaceuticals Inc launched IMCIVREE in Japan as the first approved therapy for acquired hypothalamic obesity, supported by Phase 3 TRANSCEND trial data.

13 oct 2026, 22:11 UTC

Correlated Moves

Rhythm Pharmaceuticals Inc shares advanced modestly in after-market trading, correlating with slight gains in the Direxion Daily S&P Biotech Bull 3X ETF.

12 oct 2026, 19:46 UTC

Rhythm Pharmaceuticals Inc shares fell, fluctuating within a routine range and remaining significantly below its 20-day moving average.

9 oct 2026, 20:07 UTC

Social Media

Rhythm Pharmaceuticals shares advanced after BofA set a new price target of $150, supported by positive feedback on its MC4R franchise for adult hypothalamic obesity.

8 oct 2026, 20:01 UTC

News

RBC Capital raises Rhythm Pharmaceuticals price target to $159.00 from $155.00 while maintaining an Outperform rating, citing strong market performance over five years.

7 oct 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, remaining well below their 20-day moving average and significantly lower compared to Tuesday's close.

6 oct 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving further below its 20-day moving average since Tuesday's close.

5 oct 2026, 20:30 UTC

Rhythm Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of six consecutive daily declines and remaining below its 20-day moving average.

2 oct 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, continuing a downward trend with four consecutive sessions in the red and remaining below the 20-day moving average.

1 oct 2026, 20:13 UTC

Rhythm Pharmaceuticals Inc is advancing in after-market trading, gaining ground since Thursday's close while currently trading below its 20-day moving average.

29 sept 2026, 20:07 UTC

Rhythm Pharmaceuticals Inc shares fell sharply, declining notably from Monday's close and trading well below its 20-day moving average amid ongoing pressure.

24 sept 2026, 19:25 UTC

Rhythm Pharmaceuticals Inc shares fell modestly, currently near the lower end of their one-month range and below the 20-day moving average amid broader market weakness.

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

36.21% repunte

Estimación a 12 Meses

Media 149.643 USD  36.21%

Máximo 206 USD

Mínimo 120 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

14

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat